Sandbox: Difference between revisions
| Line 41: | Line 41: | ||
<br clear="left"/> | <br clear="left"/> | ||
In [[2003]], following the outbreak of [[Severe acute respiratory syndrome]] (SARS) which had begun the prior year in Asia, and secondary cases elsewhere in the world, the [[World Health Organization]] issued a press release stating that a novel coronavirus identified by a number of laboratories was the causative agent for SARS. The virus was officially named the [[SARS coronavirus]] (SARS-CoV). The SARS epidemic resulted in over 8000 infections, about 10% of which resulted in death. | In [[2003]], following the outbreak of [[Severe acute respiratory syndrome]] (SARS) which had begun the prior year in Asia, and secondary cases elsewhere in the world, the [[World Health Organization]] issued a press release stating that a novel coronavirus identified by a number of laboratories was the causative agent for SARS. The virus was officially named the [[SARS coronavirus]] (SARS-CoV). The SARS epidemic resulted in over 8000 infections, about 10% of which resulted in death. [[X-ray crystallography]] studies performed at the [[Advanced Light Source]] of [[Lawrence Berkeley National Laboratory]] have begun to give hope of a [[vaccine]] against the disease "since [the spike protein] appears to be recognized by the immune system of the host."<ref>{{cite web | title=Learning How SARS Spikes Its Quarry | publisher=Chevy Chase, MD: Howard Hughes Medical Institute | work=Press Release PR-HHMI-05-4 | url=http://www.lightsources.org/cms/?pid=1000828 | accessmonthday=September 16 | accessyear=2005 }} </ref> | ||
For more information on SARS click [[Severe acute respiratory syndrome|here]]. | For more information on SARS click [[Severe acute respiratory syndrome|here]]. | ||
==Ref== | ==Ref== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 08:01, 29 December 2012
Do Not Delete
Shown below is a strip from a patient being cardioverted for atrial fibrillation. The patient was taking sotalol and coumadin. This is the first shock which was set at 150 joules and delivered via defibrillator pads placed with the positive in the V1 position and the negative on the back between the left scapula and the spine.
Hyperlipidemia
| Hyperlipidemia | |||||||||||||||||||||||||||||||||||||||||
| Triglycerides > 75th Percentile | NO | Type IIa | |||||||||||||||||||||||||||||||||||||||
| YES | |||||||||||||||||||||||||||||||||||||||||
| Types I, IIb, IV, V | |||||||||||||||||||||||||||||||||||||||||
| Total Cholesterol/Apo B ratio ≥ 6.2 | NO | Types IIb, IV | |||||||||||||||||||||||||||||||||||||||
Severe acute respiratory syndrome
In 2003, following the outbreak of Severe acute respiratory syndrome (SARS) which had begun the prior year in Asia, and secondary cases elsewhere in the world, the World Health Organization issued a press release stating that a novel coronavirus identified by a number of laboratories was the causative agent for SARS. The virus was officially named the SARS coronavirus (SARS-CoV). The SARS epidemic resulted in over 8000 infections, about 10% of which resulted in death. X-ray crystallography studies performed at the Advanced Light Source of Lawrence Berkeley National Laboratory have begun to give hope of a vaccine against the disease "since [the spike protein] appears to be recognized by the immune system of the host."[1]
For more information on SARS click here.
Ref
- ↑ "Learning How SARS Spikes Its Quarry". Press Release PR-HHMI-05-4. Chevy Chase, MD: Howard Hughes Medical Institute. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Unknown parameter|accessmonthday=ignored (help)